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istics were similar between treatment groups with regard to
age, weight, cancer type and Hb. The proportion of patients
transfused was similar between groups (~30%). Mean Hb
values were consistently higher in the EPO group compared to
the DARB group at Weeks 4, 8, 12, and 16. A repeated mea-
sures model showed a signiﬁcant Hb increase from BL at each
timepoint assessed in both groups as well as a signiﬁcant dif-
ference between the two groups. Mean cumulative administered
dose was 342,959 Units for EPO and 1239 mcg for DARB with
overall ESA drug cost signiﬁcantly lower in the EPO group
compared to the DARB group (EPO $4503, DARB $5669
p < 0.001). CONCLUSION: In patients with Hb < 10 g/dL
prior to ESA initiation, mean Hb levels were higher in the EPO
group than the DARB group throughout the study, with ESA
drug costs 21% lower in the EPO group than the DARB group.
Such ﬁndings inform decision-makers on ESA-associated
outcomes based on initiation as imposed in certain coverage
policies.
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OBJECTIVE: The National Cancer Institute indicates surgery,
chemotherapy, and/or radiation treatments in colorectal cancer
(CRC). Data on the effect of age and place of residence on
accessing CRC treatments in the Midwest region of United States
is limited. Therefore, using Nebraska Cancer Registry we tested
the hypothesis that CRC patients’ residence-county and age
would be associated with receipt of surgery, radiation, and che-
motherapy treatments. METHODS: In a retrospective study, we
examined treatments of 6813 CRC patients identiﬁed by incident
ICD-O CM codes between January 1998, and December 2003
from the Nebraska Cancer Registry data. In multivariate logistic
regression analyses, we studied the association of age and the
year 2003 Urban Inﬂuence Code based residence-county with
each of the three CRC treatments. RESULTS: After adjusting
for patient’s demographics, insurance payer, county-speciﬁc
provider-to-population ratio, and stage and anatomical site,
CRC patients living in small urban counties were more likely to
receive chemotherapy than were those living in rural counties
(adjusted Odds-Ratio, OR, 1.53; 95% conﬁdence-interval, CI:
1.25–1.88, p < 0.001). However, there were no signiﬁcant rural-
urban differences in receiving any CRC treatment. Compared
with 19-to-64-year-olds, patients aged 75 years and older with
local CRC stage were less likely to receive surgery (OR, 0.22;
95% CI: 0.07–0.76, p < 0.001), patients aged 75 years and older
were less likely to receive radiation (OR, 0.36; 95% CI: 0.24–
0.55, p < 0.0001), and patients aged 75 years and older were less
likely to receive chemotherapy (OR, 0.21; 95% CI: 0.16–0.27,
p < 0.0001). CONCLUSION: Nebraska CRC patients living in
rural counties were less likely to receive chemotherapy than were
those living in small urban counties. Elderly CRC patients were
less likely to receive surgery, radiation, and chemotherapy treat-
ments. Despite limitations of registry data, these ﬁndings warrant
the attention of decision-makers to age and geographic access
issues in planning future delivery of CRC treatments.
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OBJECTIVE: To assess current real-world utilization of ESAs
in patients with MDS, recent epoetin alfa (EPO) and darbepo-
etin alfa (DARB) dosing patterns and ESA treatment costs were
examined. METHODS: A retrospective analysis was conducted
using medical claims from approximately 45 health plans
nationwide during the period of Janaury 2004–June 2007.
Patients included in the study were 18 years old, had 1
claim for MDS (ICD-9 code: 238.7) prior to initiating ESA
therapy, and were newly initiated on EPO or DARB with 2
doses of either drug during the treatment period. Patients with
cancer before initiating ESA treatment for MDS were excluded.
The study period terminated with the last ESA treatment dose,
end of data availability, initial AML diagnosis, or initial stem
cell transplant, whichever occurred ﬁrst. Mean cumulative ESA
dose was used to calculate ESA cost (based on October 2007
WAC) and dose ratio (Units EPO : mcg DARB). RESULTS: The
study population consisted of 275 patients who received EPO
and 155 patients who received DARB. Mean age and gender
distribution was similar between the two groups. Mean treat-
ment duration was also similar for both groups (EPO: 75 days;
DARB: 71 days; p = 0.638). The mean cumulative ESA dose
administered was 374,415 Units for EPO and 1475 mcg for the
DARB group, corresponding to a dose ratio of 254:1 (Units
EPO: mcg DARB). Based on these doses, ESA cost was $2139
(31%) less for EPO than for DARB (EPO: $4688; DARB:
$6827; p = 0.010). CONCLUSION: These real-life clinical
practice ﬁndings in the MDS population show signiﬁcantly
lower drug cost in the EPO group compared to the DARB
group and a dose ratio of 254:1 (Units EPO : mcg DARB)
between the two agents.
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OBJECTIVE: To evaluate the presence of pharmacoeconomic
messages in the US, France, Germany, Italy, Spain, and UK for
ten representative oncology products (Alimta, Avastin, Gemzar,
Herceptin, Neulasta, Novantrone, Sutent, Tarceva, Taxotere,
and Velcade). METHODS: This qualitative assessment covered
the following data sources: 1) Government websites (Canadian
Agency for Drugs and Technologies in Health, National Insti-
tute for Health and Clinical Excellence, Institut für Qualität
und Wirtschaftlichkeit im Gesundheitswesen, La Haute
Autorité de santé, and Cochrane Reviews); 2) company spon-
sored product websites; 3) FDA and EMEA products labels;
and 4) promotional materials (detail aid brochures, direct mail,
and professional journal/newsletter ads). These data sources
were searched for relevant pharmacoeconomic messaging
including statements regarding cost, QoL, utility, patient pre-
ference, etc. RESULTS: While health technology assessments
have a clear impact on market access, speciﬁc examples of
pharmacoeconomic data in promotional messaging was limited.
Pharmacoeconomic messages, with particular focus on QoL,
were more prominent in promotional materials of oncology
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products in Europe as compared to the US. CONCLUSION:
While European regulatory bodies have long-embraced QoL/
PROs (along with efﬁcacy and safety) as key endpoints for
approval, the FDA is starting to acknowledge pharmacoeco-
nomics in their evaluations. Further research is warranted to
determine if there is a correlation between pharmacoeconomic
messaging and product uptake, with prescription or unit sales
analysis combined with large scale physician surveys on inﬂu-
ences of prescribing patterns.
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OBJECTIVE: The purpose of this study was to examine various
patient and provider characteristics associated with being pre-
scribed an aromatase inhibitors (AI) v. tamoxifen only therapy
among a cohort of North Carolina (NC) Medicaid enrollees
diagnosed with breast cancer. METHODS: Data was gathered
using the Linked NC Central Cancer Registry-Medicaid Claims
database which links NC cancer registry claims with Medicaid
data. A logistic regression model was built to determine the odds
of an individual ever receiving an AI during the study period.
RESULTS: A total of 600 patients were included, of which 451
(75.2%) and 149 (24.8%) received tamoxifen only and AI (alone
or in combination) therapy, respectively. Results showed that
patients who lived in urban areas (compared to rural), were
postmenopausal (based on age 55), had regional- or distant-
staged cancer (opposed to local or unknown), had been hospi-
talized in the year prior to treatment index, and had breast
conserving surgery (BCS) (rather than mastectomy) had 1.97
[1.29, 3.00], 2.26 [1.80, 2.83], 2.74 [1.79, 4.20], 1.87 [1.20,
2.92], 0.64 [0.41, 1.00] times the odds, respectively, of ever
receiving an AI compared to tamoxifen only. Additionally, for
every one-year increase in the time a patient started hormonal
therapy, the odds of receiving AI therapy (compared to tamoxifen
only) increased 2.26 [1.80, 2.83] fold. CONCLUSION: The
differences in antiestrogenic treatment type based on whether the
patient visited a hospital in the year prior to the study and in
whether the patient lived in urban or rural area may represent
disparities in access to advances in care. Furthermore, it may be
the case that women who undergo mastectomy or who have
locally staged cancer are not being treated aggressively enough
with novel antiestrogenic therapies.
PCN89
DRUG UTILIZATION PATTERNS AND COSTS FOR
ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN A
MANAGED CARE CANCER POPULATION RECEIVING
CHEMOTHERAPY
Gosselin A1, Lafeuille MH2, Bookhart B3, Lefebvre P2, Mckenzie RS3,
Vekeman F1, Piech CT3
1Groupe d’Analyse, Ltée, Montréal, QC, Canada, 2Groupe d’analyse,
Ltee, Montreal, QC, Canada, 3Ortho Biotech Clinical Affairs, LLC,
Bridgewater, NJ, USA
OBJECTIVE: To assess current utilization patterns and costs for
epoetin alfa (EPO) and darbepoetin alfa (DARB), two ESAs,
in managed care cancer patients receiving chemotherapy.
METHODS: Medical claims from the Ingenix Impact National
Managed Care Database between January 2006 and June 2007
were analyzed. Patients included were 18 years old, had 1
claim for cancer within 90 days prior to treatment initiation,
were newly initiated on EPO or DARB with 2 doses of either
drug, and received chemotherapy during ESA treatment. Mean
cumulative ESA dose was used to calculate ESA cost (based on
October 2007 wholesale acquisition cost [WAC]) and dose ratio.
RESULTS: A total of 2322 EPO and 4353 DARB formed the
study population. EPO patients were older (57.7 vs. 55.7 years;
p < 0.0001) and a lower proportion were women (65% vs. 69%;
p = 0.0002), compared to DARB patients. Mean ESA treatment
duration was slightly longer in the EPO group (59 vs. 55 days;
p = 0.0001). The mean cumulative dose (SD) was 312,723
(255,432) Units for EPO and 1174 (833) mcg for DARB, result-
ing in a dose ratio of 266:1 (Units EPO : mcg DARB). Based on
these doses, WAC-based ESA cost was 28% less for EPO than
for DARB (EPO $3915; DARB $5434; p < 0.0001). A sensitivity
analysis using January 2008 average sales price +6% also indi-
cated lower cost for EPO (EPO $2803; DARB $3396;
p < .0001). This ﬁnding was also maintained after adjusting for
age, gender, treatment duration, payer type, type of malignan-
cies, cancer treatments, and severity indicators, (adjusted cost
difference: $1788, p < 0.0001). CONCLUSION: This observa-
tional study of 6675 cancer patients reported a dose ratio of
266:1 which resulted in a 28% lower drug cost in the EPO
group compared to the DARB group. These ﬁndings provide
greater understanding of current real-world ESA utilization in
the managed care setting.
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OBJECTIVE: Organized nationwide screening programme for
cervical cancer was introduced in Hungary in 2003. The aim of
this study is to analyze the three year screening rate (coverage)
of the organized cervical cancer screening programme in
women aged less than 25 years. Although women under 25
years are out of the scope of the organized screening pro-
gramme, but opportunistic screening may be applied.
METHODS: The data derive from the ﬁnancial database of
the National Health Insurance Fund Administration (OEP) of
Hungary covering the period of 2000–2002 (without organized
screening) and 2003–2005 (with organized screening). We cal-
culated the three-year screening rate for 2003–2005 according
to the age-group of women less than 25 years (15–19 and
20–24). Screening is deﬁned with cytological examination of
Papanicolau smear and includes all smears taken either within
or outside of the organized programme. RESULTS: The three-
year screening rate of women aged 25–64 years was 52.65 %
in 2003–2005. The coverage of women under 25 years was the
following in 2003–2005: 15–19 years: 31.94 %; 20–24 years:
61.20 %. Comparing this values to the coverage of 2000–2002
(without organized screening) we found a decreasing tendency
in these two age-groups: 15–19 years: -0.06 percent point
decrease (non-signiﬁcant), 20–24 years: -6.28 percent point
decrease (p < 0.01). CONCLUSION: We found that coverage
of women aged 20–24 being out of the scope of the organized
cervical cancer screening programme is higher (61.2 %) than
the average of target age group of 25–64 years (52.65). Despite
of this ﬁnding, the coverage of women 15–19 and 20–24
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